[Form 4] Columbia Sportswear Co Insider Trading Activity
Ionis Pharmaceuticals (IONS) 鈥� CEO Form 4 insider transaction dated 07/30/25
Chief Executive Officer Brett P. Monia exercised 2,432 non-qualified stock options at an exercise price of $32.60 (transaction code M) and immediately sold the same 2,432 shares of common stock at $45.00 (transaction code S) pursuant to a Rule 10b5-1 plan adopted 08/13/24. Following the sale, Monia鈥檚 direct holdings stand at 179,820 common shares, while he retains 99,057 options outstanding. The options exercised were granted 01/03/23 and expire 01/02/32.
The sale represents roughly 1.4 % of his direct equity stake and appears routine given the pre-arranged trading plan. There is no indication of additional material events or changes to company fundamentals within the filing.
Ionis Pharmaceuticals (IONS) 鈥� Transazione insider del CEO Form 4 datata 30/07/25
Il Chief Executive Officer Brett P. Monia ha esercitato 2.432 opzioni azionarie non qualificate a un prezzo di esercizio di 32,60 $ (codice transazione M) e ha immediatamente venduto le stesse 2.432 azioni ordinarie a 45,00 $ (codice transazione S) secondo un piano Rule 10b5-1 adottato il 13/08/24. Dopo la vendita, le partecipazioni dirette di Monia ammontano a 179.820 azioni ordinarie, mentre mantiene 99.057 opzioni ancora in essere. Le opzioni esercitate sono state concesse il 03/01/23 e scadono il 02/01/32.
La vendita rappresenta circa l'1,4% della sua partecipazione diretta e appare di routine, dato il piano di trading predefinito. Non vi 猫 alcuna indicazione di eventi materiali aggiuntivi o cambiamenti nei fondamentali dell'azienda all'interno della comunicazione.
Ionis Pharmaceuticals (IONS) 鈥� Transacci贸n insider del CEO Formulario 4 fechada el 30/07/25
El Director Ejecutivo Brett P. Monia ejerci贸 2.432 opciones sobre acciones no calificadas a un precio de ejercicio de 32,60 $ (c贸digo de transacci贸n M) y vendi贸 inmediatamente las mismas 2.432 acciones ordinarias a 45,00 $ (c贸digo de transacci贸n S) conforme a un plan Rule 10b5-1 adoptado el 13/08/24. Tras la venta, las participaciones directas de Monia ascienden a 179.820 acciones ordinarias, mientras que conserva 99.057 opciones vigentes. Las opciones ejercidas fueron concedidas el 03/01/23 y expiran el 02/01/32.
La venta representa aproximadamente el 1,4% de su participaci贸n directa y parece rutinaria dado el plan de trading preestablecido. No hay indicios de eventos materiales adicionales o cambios en los fundamentos de la empresa en la presentaci贸n.
鞎勳澊鞓る媹鞀� 韺岆鞀堩嫲旎姢(IONS) 鈥� CEO Form 4 雮措秬鞛� 瓯半灅 2025雲� 7鞗� 30鞚检瀽
斓滉碃瓴届榿鞛� Brett P. Monia電� 頄夓偓臧�瓴� $32.60搿� 2,432臧滌潣 牍勳瀽瓴� 鞀ろ啞鞓奠厴鞚� 頄夓偓(瓯半灅 旖旊摐 M)頃橁碃, 歃夓嫓 臧欖潃 2,432欤检潣 氤错喌欤茧ゼ $45.00(瓯半灅 旖旊摐 S)鞐� 毵る弰頄堨姷雼堧嫟. 鞚措姅 2024雲� 8鞗� 13鞚� 毂勴儩霅� Rule 10b5-1 瓿勴殟鞐� 霐半ジ 瓴冹瀰雼堧嫟. 毵る弰 頉� Monia鞚� 歆侅爲 氤挫湢 欤检嫕靾橂姅 179,820欤检澊氅�, 鞎勳 頄夓偓霅橃 鞎婌潃 鞓奠厴鞚� 99,057臧滌瀰雼堧嫟. 頄夓偓霅� 鞓奠厴鞚� 2023雲� 1鞗� 3鞚� 攵�鞐悩鞐堦碃 2032雲� 1鞗� 2鞚� 毵岆霅╇媹雼�.
鞚措矆 毵る弰電� 攴胳潣 歆侅爲 歆�攵勳潣 鞎� 1.4%鞐� 頃措嫻頃橂┌, 靷爠 瓿勴殟霅� 瓯半灅 瓿勴殟鞐� 霐半ジ 鞚检儊鞝侅澑 瓯半灅搿� 氤挫瀰雼堧嫟. 鞝滌稖霅� 靹滊 雮挫棎靹� 於旉皜鞝侅澑 欷戨寑頃� 靷贝鞚措倶 須岇偓 旮半掣 靷暛鞚� 氤�頇旊姅 雮橅儉雮橃 鞎婌姷雼堧嫟.
Ionis Pharmaceuticals (IONS) 鈥� Transaction d鈥檌niti茅 du PDG Formulaire 4 dat茅e du 30/07/25
Le Directeur G茅n茅ral Brett P. Monia a exerc茅 2 432 options d鈥檃chat d鈥檃ctions non qualifi茅es 脿 un prix d鈥檈xercice de 32,60 $ (code transaction M) et a imm茅diatement vendu les m锚mes 2 432 actions ordinaires 脿 45,00 $ (code transaction S) conform茅ment 脿 un plan Rule 10b5-1 adopt茅 le 13/08/24. Apr猫s la vente, les avoirs directs de Monia s鈥櫭﹍猫vent 脿 179 820 actions ordinaires, tandis qu鈥檌l d茅tient encore 99 057 options en circulation. Les options exerc茅es ont 茅t茅 attribu茅es le 03/01/23 et expirent le 02/01/32.
La vente repr茅sente environ 1,4 % de sa participation directe et semble routini猫re compte tenu du plan de trading pr茅茅tabli. Aucun 茅v茅nement mat茅riel suppl茅mentaire ni changement dans les fondamentaux de l鈥檈ntreprise n鈥檈st mentionn茅 dans le d茅p么t.
Ionis Pharmaceuticals (IONS) 鈥� CEO Insider-Transaktion Form 4 vom 30.07.25
Chief Executive Officer Brett P. Monia 眉bte 2.432 nicht qualifizierte Aktienoptionen zu einem Aus眉bungspreis von 32,60 $ (Transaktionscode M) aus und verkaufte unmittelbar danach dieselben 2.432 Stammaktien zu 45,00 $ (Transaktionscode S) gem盲脽 einem am 13.08.24 angenommenen Rule 10b5-1-Plan. Nach dem Verkauf h盲lt Monia 179.820 Stammaktien direkt, w盲hrend er noch 99.057 ausstehende Optionen besitzt. Die ausge眉bten Optionen wurden am 03.01.23 gew盲hrt und laufen am 02.01.32 ab.
Der Verkauf entspricht etwa 1,4 % seiner direkten Beteiligung und erscheint routinem盲脽ig aufgrund des vorab festgelegten Handelsplans. In der Meldung gibt es keine Hinweise auf weitere wesentliche Ereignisse oder 脛nderungen der Unternehmensgrundlagen.
- Transaction conducted under a Rule 10b5-1 plan, indicating advance scheduling and reducing the likelihood of information-based trading.
- CEO retains 179,820 shares, maintaining significant alignment with shareholders.
- Net sale of 2,432 shares by the CEO, though modest, may be viewed as a slight negative sentiment signal.
Insights
TL;DR: Small, pre-planned CEO share sale鈥攏eutral signal for investors.
Monia converted 2,432 options into stock at $32.60 and sold them at $45, realising a ~$30k gross gain. Because the sale was executed under an established Rule 10b5-1 plan and equals only ~1.4 % of his 180k-share position, it does not materially alter insider ownership or suggest a directional view on Ionis fundamentals. No other derivatives were affected; 99,057 options remain. Overall, the filing is routine and should have minimal market impact.
Ionis Pharmaceuticals (IONS) 鈥� Transazione insider del CEO Form 4 datata 30/07/25
Il Chief Executive Officer Brett P. Monia ha esercitato 2.432 opzioni azionarie non qualificate a un prezzo di esercizio di 32,60 $ (codice transazione M) e ha immediatamente venduto le stesse 2.432 azioni ordinarie a 45,00 $ (codice transazione S) secondo un piano Rule 10b5-1 adottato il 13/08/24. Dopo la vendita, le partecipazioni dirette di Monia ammontano a 179.820 azioni ordinarie, mentre mantiene 99.057 opzioni ancora in essere. Le opzioni esercitate sono state concesse il 03/01/23 e scadono il 02/01/32.
La vendita rappresenta circa l'1,4% della sua partecipazione diretta e appare di routine, dato il piano di trading predefinito. Non vi 猫 alcuna indicazione di eventi materiali aggiuntivi o cambiamenti nei fondamentali dell'azienda all'interno della comunicazione.
Ionis Pharmaceuticals (IONS) 鈥� Transacci贸n insider del CEO Formulario 4 fechada el 30/07/25
El Director Ejecutivo Brett P. Monia ejerci贸 2.432 opciones sobre acciones no calificadas a un precio de ejercicio de 32,60 $ (c贸digo de transacci贸n M) y vendi贸 inmediatamente las mismas 2.432 acciones ordinarias a 45,00 $ (c贸digo de transacci贸n S) conforme a un plan Rule 10b5-1 adoptado el 13/08/24. Tras la venta, las participaciones directas de Monia ascienden a 179.820 acciones ordinarias, mientras que conserva 99.057 opciones vigentes. Las opciones ejercidas fueron concedidas el 03/01/23 y expiran el 02/01/32.
La venta representa aproximadamente el 1,4% de su participaci贸n directa y parece rutinaria dado el plan de trading preestablecido. No hay indicios de eventos materiales adicionales o cambios en los fundamentos de la empresa en la presentaci贸n.
鞎勳澊鞓る媹鞀� 韺岆鞀堩嫲旎姢(IONS) 鈥� CEO Form 4 雮措秬鞛� 瓯半灅 2025雲� 7鞗� 30鞚检瀽
斓滉碃瓴届榿鞛� Brett P. Monia電� 頄夓偓臧�瓴� $32.60搿� 2,432臧滌潣 牍勳瀽瓴� 鞀ろ啞鞓奠厴鞚� 頄夓偓(瓯半灅 旖旊摐 M)頃橁碃, 歃夓嫓 臧欖潃 2,432欤检潣 氤错喌欤茧ゼ $45.00(瓯半灅 旖旊摐 S)鞐� 毵る弰頄堨姷雼堧嫟. 鞚措姅 2024雲� 8鞗� 13鞚� 毂勴儩霅� Rule 10b5-1 瓿勴殟鞐� 霐半ジ 瓴冹瀰雼堧嫟. 毵る弰 頉� Monia鞚� 歆侅爲 氤挫湢 欤检嫕靾橂姅 179,820欤检澊氅�, 鞎勳 頄夓偓霅橃 鞎婌潃 鞓奠厴鞚� 99,057臧滌瀰雼堧嫟. 頄夓偓霅� 鞓奠厴鞚� 2023雲� 1鞗� 3鞚� 攵�鞐悩鞐堦碃 2032雲� 1鞗� 2鞚� 毵岆霅╇媹雼�.
鞚措矆 毵る弰電� 攴胳潣 歆侅爲 歆�攵勳潣 鞎� 1.4%鞐� 頃措嫻頃橂┌, 靷爠 瓿勴殟霅� 瓯半灅 瓿勴殟鞐� 霐半ジ 鞚检儊鞝侅澑 瓯半灅搿� 氤挫瀰雼堧嫟. 鞝滌稖霅� 靹滊 雮挫棎靹� 於旉皜鞝侅澑 欷戨寑頃� 靷贝鞚措倶 須岇偓 旮半掣 靷暛鞚� 氤�頇旊姅 雮橅儉雮橃 鞎婌姷雼堧嫟.
Ionis Pharmaceuticals (IONS) 鈥� Transaction d鈥檌niti茅 du PDG Formulaire 4 dat茅e du 30/07/25
Le Directeur G茅n茅ral Brett P. Monia a exerc茅 2 432 options d鈥檃chat d鈥檃ctions non qualifi茅es 脿 un prix d鈥檈xercice de 32,60 $ (code transaction M) et a imm茅diatement vendu les m锚mes 2 432 actions ordinaires 脿 45,00 $ (code transaction S) conform茅ment 脿 un plan Rule 10b5-1 adopt茅 le 13/08/24. Apr猫s la vente, les avoirs directs de Monia s鈥櫭﹍猫vent 脿 179 820 actions ordinaires, tandis qu鈥檌l d茅tient encore 99 057 options en circulation. Les options exerc茅es ont 茅t茅 attribu茅es le 03/01/23 et expirent le 02/01/32.
La vente repr茅sente environ 1,4 % de sa participation directe et semble routini猫re compte tenu du plan de trading pr茅茅tabli. Aucun 茅v茅nement mat茅riel suppl茅mentaire ni changement dans les fondamentaux de l鈥檈ntreprise n鈥檈st mentionn茅 dans le d茅p么t.
Ionis Pharmaceuticals (IONS) 鈥� CEO Insider-Transaktion Form 4 vom 30.07.25
Chief Executive Officer Brett P. Monia 眉bte 2.432 nicht qualifizierte Aktienoptionen zu einem Aus眉bungspreis von 32,60 $ (Transaktionscode M) aus und verkaufte unmittelbar danach dieselben 2.432 Stammaktien zu 45,00 $ (Transaktionscode S) gem盲脽 einem am 13.08.24 angenommenen Rule 10b5-1-Plan. Nach dem Verkauf h盲lt Monia 179.820 Stammaktien direkt, w盲hrend er noch 99.057 ausstehende Optionen besitzt. Die ausge眉bten Optionen wurden am 03.01.23 gew盲hrt und laufen am 02.01.32 ab.
Der Verkauf entspricht etwa 1,4 % seiner direkten Beteiligung und erscheint routinem盲脽ig aufgrund des vorab festgelegten Handelsplans. In der Meldung gibt es keine Hinweise auf weitere wesentliche Ereignisse oder 脛nderungen der Unternehmensgrundlagen.
FAQ
How many Ionis (IONS) shares did the CEO sell?
What price did the CEO pay to exercise his stock options?
Does the CEO still own Ionis stock after the sale?
Was the sale part of a 10b5-1 trading plan?
What percentage of the CEO's holdings was sold?
